-

02:22:49 AM

SAVA Stock News

SAVA - Cassava Sciences Inc

01/24/23 9:15 AM

Nasdaq : SAVA

clinical trialhigh short

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets. 47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less than 5 points on

RHEA-AI

neutral

12/20/22 9:15 AM

Nasdaq : SAVA

managementhigh short

Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD

Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passing of a

RHEA-AI

neutral

12/06/22 9:15 AM

Nasdaq : SAVA

high short

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06,

RHEA-AI

neutral

11/22/22 12:29 PM

Nasdaq : SAVA

offeringhigh short

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667

RHEA-AI

neutral

11/18/22 1:30 PM

Nasdaq : SAVA

offeringhigh short

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and

RHEA-AI

neutral

11/07/22 9:00 AM

Nasdaq : SAVA

earningshigh short

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage

RHEA-AI

negative

11/03/22 9:15 AM

Nasdaq : SAVA

high short

Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ page

RHEA-AI

very negative

10/27/22 9:15 AM

Nasdaq : SAVA

managementhigh short

Cassava Sciences Announces Expansion of Leadership Team

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on

RHEA-AI

neutral

10/13/22 9:15 AM

Nasdaq : SAVA

high short

Cassava Sciences Announces Initiation of an Open-label Extension Study

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage

RHEA-AI

neutral

09/08/22 9:15 AM

Nasdaq : SAVA

conferenceshigh short

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global Investment

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next